A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs GDC 0853 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Genentech
- 27 Feb 2018 Planned End Date changed from 30 Jun 2019 to 29 Jun 2019.
- 27 Feb 2018 Planned primary completion date changed from 30 Jun 2019 to 29 Jun 2019.
- 05 May 2017 Status changed from not yet recruiting to recruiting.